Digestive, Liver and Metabolic Health: Traditional Use and a Retracted Study
Digestive complaints are the most consistent traditional use of shampoo ginger across its entire range — Hawaii, Malaysia, Indonesia, Vietnam, Thailand and India all independently arrived at some version of it. The modern research record is more complicated than that consistency suggests: its single most-cited supporting study was formally retracted in 2023 for data-integrity problems, and what survives is a smaller, animal-only body of work on the liver and on diabetic organ damage. This page covers both honestly — the retraction in full, because understanding exactly what went wrong matters more than treating it as a footnote, and what remains once it is set aside.
Table of Contents
- Traditional Digestive Use Across Four Regions
- The Retracted Gastroprotective Study: What Happened
- What Survives: Isolated Urease Inhibition
- Hepatoprotective Animal Evidence
- Fatty Liver and Lipid-Lowering Animal Evidence
- Diabetic Nephropathy and Retinopathy Protection
- Why One Research Group's Repeated Results Need a Caveat
- Why a Retraction Matters More Than a Missing Study
- Human Evidence: None
- Cautions
- Key Research Papers
- Connections
- Featured Videos
Traditional Digestive Use Across Four Regions
The main Wild Ginger page lists this already, and it is worth restating with emphasis, because it is the most geographically consistent traditional claim the plant carries — more consistent than the hair-rinse use, which is essentially a Pacific/Hawaiian tradition, or the cancer claims, which are entirely modern laboratory findings with no traditional precedent at all. Inflammation and pain, by contrast, do have a traditional record: a 2011 review of the plant notes that rhizome extracts have been used in Malay traditional medicine for "inflammatory- and pain-mediated diseases, worm infestation and diarrhea."
- Hawaii. The pounded rhizome was used for stomach complaints, alongside sprains, bruises and aching muscles.
- Malaysia and Indonesia. Lempoyang rhizome is a jamu ingredient specifically for indigestion, flatulence and loss of appetite — the clearest "carminative" framing among the four traditions.
- Vietnam. Gừng gió is used for digestive complaints and for what traditional Vietnamese medicine (thuốc nam) describes as stagnation of qi and blood, and appears in liver-tonic formulas — the only tradition that explicitly links the plant to the liver specifically, which is echoed, unexpectedly, by the animal hepatoprotective literature discussed below.
- Thailand and India. Used for inflammatory and gastrointestinal complaints together, reflecting the same overlap between digestive and anti-inflammatory framing this site's evidence doctrine notes is common across many culinary-medicinal rhizomes.
Four independent regions landing on broadly the same organ system is a genuinely notable ethnobotanical pattern — independent traditional use across unconnected cultures is a real, if weak, form of signal. It is not, on its own, evidence of efficacy; it is evidence that the plant has been used this way for a long time in unrelated places, which is a different and more modest claim.
The Retracted Gastroprotective Study: What Happened
In March 2015, a study titled "Antisecretory, gastroprotective, antioxidant and anti-Helicobacter pylori activity of zerumbone from Zingiber zerumbet" was published in PLoS One. It reported that zerumbone reduced gastric acid secretion, protected the stomach lining against induced ulcers, showed antioxidant activity, and worked against H. pylori — in other words, essentially the complete gastroprotective case in a single paper. For eight years, this was the flagship citation for shampoo ginger's digestive benefits.
In November 2023, PLoS One's editors formally retracted it. The retraction notice is specific about why, and the specifics are worth stating precisely rather than summarising as a vague "data concerns":
- The editors found that multiple figures appeared to reuse images from other, previously published studies while being presented as representing different experimental conditions in this paper — specifically flagged were figures 2A/2B, figure 3B (which matched a previously published figure when rotated), and figures 5A/5C.
- The corresponding author's explanation for the similarity in figures 2A/2B was that the panels "represent the same experimental conditions" as figures in other papers — but the editors reviewed the methodology of those other studies and determined the control-group conditions were not actually identical, undermining that explanation.
- For the other overlapping images, the author stated that "incorrect images were inadvertently used during figure preparation."
- Replacement figures were offered, but the editors concluded they "did not resolve the editorial concerns pertaining to the overall data-handling for this study and the reliability of the results" — meaning the journal's final position is not merely that some figures were wrong, but that the underlying data-handling for the whole study could not be trusted.
This is a serious retraction, not a minor correction. It removes the single strongest piece of evidence for shampoo ginger having any direct gastroprotective, antisecretory or anti-H. pylori effect as a whole preparation. Both the original paper and its retraction notice remain findable on PubMed — this page cites both deliberately, so that a reader who encounters the original claim elsewhere (in a supplement marketing page, an older secondary source, or an AI-generated summary trained on data predating late 2023) can find the retraction just as easily.
What Survives: Isolated Urease Inhibition
The retraction does not erase every finding connecting zerumbone to H. pylori. A separate, later, non-retracted 2021 study found zerumbone inhibits the bacterium's urease enzyme specifically — a real, standing finding, but a much narrower one than the retracted paper's claims. Urease inhibition in an isolated-enzyme assay does not, by itself, establish antisecretory activity, gastroprotection against ulcers, or clearance of a living infection in a real stomach, where H. pylori is protected by mucus and biofilm in ways an isolated enzyme is not. The fuller discussion of this finding and its limits is on the Antimicrobial and Antifungal Properties page.
Put together: the retraction removed the broad claim, and what remains is one narrow, mechanistically real but clinically unproven enzyme-inhibition result. That is a meaningfully weaker evidence base than existed in the literature before November 2023, and weaker still than most secondary sources currently reflect.
Hepatoprotective Animal Evidence
Separately from the gastric-specific claims above, a real body of animal work tests zerumbone and rhizome extracts against liver injury — connecting, loosely, to the Vietnamese tradition's specific liver-tonic framing.
- A 2018 Malaysian study found zerumbone had hepatoprotective effects against paracetamol (acetaminophen)-induced acute hepatotoxicity in rats — a standard, well-validated model of drug-induced liver injury, since paracetamol overdose is a leading real-world cause of acute liver failure. The rats received paracetamol (1000 mg/kg) and then zerumbone (25 mg/kg) at 0 h and 4 h after the paracetamol injection. After 24 hours the zerumbone-treated rats had lower ALT (P = 0.041) and AST (P = 0.044) liver enzymes than rats given paracetamol alone, liver cells of normal structure with no vacuolisation or necrosis, and a lower neutrophil count (P = 0.037), which the authors read as suppression of the inflammation caused by the overdose.
- A 2019 study found dietary zerumbone ameliorated hepatotoxin-mediated both acute and chronic liver injury in mice — a broader claim than the single-insult paracetamol study, testing sustained as well as one-off damage.
Fatty Liver and Lipid-Lowering Animal Evidence
A cluster of studies from a single Taiwanese research group tested zerumbone and ethanol extracts of the rhizome against diet-induced metabolic liver disease in hamsters fed a high-fat diet:
- A 2014 study found zerumbone itself had lipid-lowering effects in high-fat-diet-induced hyperlipidemic hamsters.
- Two closely related 2013–2014 studies — one testing the ethanol extract, one testing isolated zerumbone — both found attenuation of non-alcoholic fatty liver disease (NAFLD) in the same hamster high-fat-diet model. Testing both the crude extract and the isolated compound against the same disease model is methodologically useful, since it helps establish that zerumbone specifically, not some other extract component, is doing the work — though both papers share the same authorship group and the same core model.
Diabetic Nephropathy and Retinopathy Protection
The same research group extended this work to diabetic organ damage specifically, using the standard streptozotocin-induced diabetes rat model (streptozotocin selectively destroys insulin-producing pancreatic cells, producing a reliable type-1-like diabetes model used throughout pharmacology research):
- A 2013 study found zerumbone ameliorated streptozotocin-induced diabetic nephropathy (kidney damage) in rats by reducing the hyperglycemia-induced inflammatory response — connecting back to the metabolic-inflammation cell-culture work (high glucose plus THP-1 macrophages) discussed on the Inflammation page. A companion study the same year found the ethanol extract produced a similar attenuation of diabetic nephropathy. In that study diabetic rats were given the extract (200 or 300 mg/kg a day) or the diabetes drug metformin (100 mg/kg a day) by mouth for 8 weeks, and the authors report that the extract "displayed similar characteristics to those of metformin in reducing hyperglycemia and renal dysfunction in diabetic rats." This is a rat comparison, not a test in people.
- A separate, direct nephroprotective finding (not diabetes-specific) showed a Zingiber zerumbet ethyl acetate extract protected against paracetamol-induced nephrotoxicity and oxidative stress in rats — the kidney analogue of the paracetamol-hepatoprotection finding above, from a different research group.
- A 2016 study extended the same group's diabetic-complications work to the eye, finding the ethanol extract mitigated vascular lesions in the diabetic retina — diabetic retinopathy is a leading cause of adult blindness, and vascular protection in this model is a distinct, if related, finding from the kidney work.
- A second 2016 paper from the same group tested pure zerumbone rather than the extract in the eyes of diabetic rats. Zerumbone at 40 mg/kg by mouth once a day for 8 weeks lowered plasma glucose (32.5% ± 5.7% lower) and glycosylated hemoglobin (29.2% ± 3.4% lower), and the disarrangement and thinning of the retinal layers seen in untreated diabetic rats were reversed. This is again a rat study from the same laboratory.
Why One Research Group's Repeated Results Need a Caveat
It is worth naming directly what a close read of the author lists in the two sections above shows: the non-alcoholic fatty liver disease, lipid-lowering, and diabetic-nephropathy studies are substantially the output of one Taiwanese laboratory group (the combination of Tzeng TF, Liou SS, Chang CJ and Liu IM recurs, in overlapping order, across five separate papers spanning 2013 to 2016, with the diabetic-retina and wound-healing studies adding one or two additional names to the same core group). This is not a criticism of the work's validity — a lab building a coherent, multi-organ research programme around one compound is normal and often produces exactly the kind of mechanistically consistent picture assembled across this page's sections.
But it does mean this literature has not yet been independently replicated by a separate laboratory, which is a meaningfully different evidentiary position from a finding confirmed by unconnected research groups working separately (the pattern seen, for comparison, in the Candida biofilm literature, where a Korean group and a Brazilian group reached compatible conclusions independently). "One lab, five papers, one core model" is a different evidence position from "five labs, one paper each" — both look identical when summarised as "five studies show," and only checking the author lists reveals the difference.
Why a Retraction Matters More Than a Missing Study
This site's evidence doctrine treats absence of evidence as a finding in its own right, distinct from a negative result. A retraction is a third, distinct category again, and arguably a more serious one than either: it is not that gastroprotection was never tested (absent), and not that it was tested properly and failed (negative) — it is that a positive result was published, cited, and incorporated into the plant's reputation for eight years, before the underlying data-handling was found unreliable enough to withdraw the paper entirely. The retracted claim may still turn up in supplement marketing, older articles, or anywhere that copied the original 2015 abstract without checking whether it still stands — which is precisely why this page names the retraction explicitly rather than simply omitting the citation and leaving a silent gap where a confident reader might assume nothing was ever claimed.
Human Evidence: None
As with the inflammation claims discussed on this Benefits leg's companion page, no human trial exists for any digestive, hepatoprotective or metabolic claim discussed on this page. The one human study of zerumbone that does exist — the 2024 cancer-patient quality-of-life pilot detailed on the Cancer page — did not measure liver enzymes, digestive symptoms, glucose control or any outcome relevant to this page's claims. That pilot was a non-randomised, open study of 400 mg of zerumbone twice a day in 35 people with solid tumours and no treatment options, of whom 16 completed the eight weeks; the authors reported that the preparation "showed low toxicity" and wrote that a randomised placebo-controlled study is needed to confirm their results. Every finding above is a rat, mouse or hamster study.
A 2024 scoping review of the plant's medicinal properties gives the count plainly: its results "included 54 articles consisting of animal studies, while there were no published human studies." The same review notes that the ethanolic extract was well tolerated for up to 28 days in those animal studies, and that comprehensive safety data are still needed before clinical trials can be run.
Cautions
- No study shows shampoo ginger treats a Helicobacter pylori infection, an ulcer, or any diagnosed digestive or liver condition. The strongest supporting study for direct gastroprotective and anti-H. pylori action was retracted, and what remains is animal-only.
- The streptozotocin findings above are rodent results; no study has tested shampoo ginger in people with diabetes, diabetic kidney disease or diabetic retinopathy. They are protective/attenuation findings in a rodent disease model, not a tested treatment for an existing human diagnosis.
- Paracetamol (acetaminophen) overdose is a medical emergency treated with N-acetylcysteine, not with zerumbone or any herbal preparation — the hepatoprotective animal studies above are pharmacology research, not a home-treatment protocol.
- The main Wild Ginger page covers the pregnancy, surgical, and general safety cautions that apply regardless of which specific claim is being considered.
Key Research Papers
- Sidahmed HM, Hashim NM, Abdulla MA, et al. (2015). Antisecretory, gastroprotective, antioxidant and anti-Helicobacter pylori activity of zerumbone from Zingiber zerumbet (L.) Smith. PLoS One, 10(3):e0121060. [RETRACTED — see next entry] — PubMed PMID: 25798602
- PLOS ONE Editors (2023). Retraction: Antisecretory, Gastroprotective, Antioxidant and Anti-Helicobacter Pylori Activity of Zerumbone from Zingiber Zerumbet (L.) Smith. PLoS One, 18(11):e0294009. — PubMed PMID: 37948334
- Woo HJ, Yang JY, Lee P, Kim JB, Kim SH (2021). Zerumbone Inhibits Helicobacter pylori Urease Activity. Molecules, 26(9). — PubMed PMID: 34062878
- Hamid A, Lee LS, Karim SR, Jufri NF (2018). Hepatoprotective Effects of Zerumbone against Paracetamol-Induced Acute Hepatotoxicity in Rats. The Malaysian Journal of Medical Sciences, 25(2):64–71. — PubMed PMID: 30918456
- Kim JW, Yang D, Jeong H, et al. (2019). Dietary zerumbone, a sesquiterpene, ameliorates hepatotoxin-mediated acute and chronic liver injury in mice. Phytotherapy Research, 33(5):1538–1550. — PubMed PMID: 30868670
- Tzeng TF, Lu HJ, Liou SS, Chang CJ, Liu IM (2014). Lipid-lowering effects of zerumbone, a natural cyclic sesquiterpene of Zingiber zerumbet Smith, in high-fat diet-induced hyperlipidemic hamsters. Food and Chemical Toxicology, 69:132–9. — PubMed PMID: 24709573
- Chang CJ, Liou SS, Tzeng TF, Liu IM (2014). The ethanol extract of Zingiber zerumbet Smith attenuates non-alcoholic fatty liver disease in hamsters fed on high-fat diet. Food and Chemical Toxicology, 65:33–42. — PubMed PMID: 24342243
- Tzeng TF, Liou SS, Chang CJ, Liu IM (2013). Zerumbone, a Natural Cyclic Sesquiterpene of Zingiber zerumbet Smith, Attenuates Nonalcoholic Fatty Liver Disease in Hamsters Fed on High-Fat Diet. Evidence-Based Complementary and Alternative Medicine, 2013:303061. — PubMed PMID: 24223615
- Tzeng TF, Liou SS, Chang CJ, Liu IM (2013). Zerumbone, a tropical ginger sesquiterpene, ameliorates streptozotocin-induced diabetic nephropathy in rats by reducing the hyperglycemia-induced inflammatory response. Nutrition & Metabolism, 10(1):64. — PubMed PMID: 24499158
- Tzeng TF, Liou SS, Chang CJ, Liu IM (2013). The Ethanol Extract of Zingiber zerumbet Attenuates Streptozotocin-Induced Diabetic Nephropathy in Rats. Evidence-Based Complementary and Alternative Medicine, 2013:340645. — PubMed PMID: 23476687
- Abdul Hamid Z, Budin SB, Wen Jie N, et al. (2012). Nephroprotective effects of Zingiber zerumbet Smith ethyl acetate extract against paracetamol-induced nephrotoxicity and oxidative stress in rats. Journal of Zhejiang University Science B, 13(3):176–85. — PubMed PMID: 22374609
- Hong TY, Tzeng TF, Liou SS, Liu IM (2016). The ethanol extract of Zingiber zerumbet rhizomes mitigates vascular lesions in the diabetic retina. Vascular Pharmacology, 76:18–27. — PubMed PMID: 26319672
- Tzeng TF, Liou SS, Tzeng YC, Liu IM (2016). Zerumbone, a Phytochemical of Subtropical Ginger, Protects against Hyperglycemia-Induced Retinal Damage in Experimental Diabetic Rats. Nutrients, 8(8):449. — PubMed PMID: 27463726
- Yob NJ, Jofrry SM, Affandi MM, Teh LK, Salleh MZ, Zakaria ZA (2011). Zingiber zerumbet (L.) Smith: A Review of Its Ethnomedicinal, Chemical, and Pharmacological Uses. Evidence-Based Complementary and Alternative Medicine, 2011:543216. — PubMed PMID: 21584247
- Chan JSW, Lim XY, Japri N, Ahmad IF, Tan TYC (2024). Zingiber zerumbet: A Scoping Review of its Medicinal Properties. Planta Medica, 90(3):204–218. — PubMed PMID: 38035621
- de Queiroz LV, Neto JF, Fonseca FLA, Pinheiro CC, Del Giglio A (2024). Bitter ginger (Zingiber zerumbet) for patients with solid tumors with no treatment options: A pilot clinical study. Complementary Therapies in Medicine, 80:103021. — PubMed PMID: 38199583